Lymphatic Filariasis Clinical Trial
Official title:
Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study
This study, conducted in Mali, West Africa, will determine whether a new treatment regimen
for lymphatic filariasis can eliminate the disease more quickly than the standard regimen.
Lymphatic filariasis is caused by infection with very small filarial worms called Wuchereria
bancrofti that are spread by mosquitoes. The disease can cause swelling of the arms, legs,
breast and genitalia and can progress to permanent swelling of the legs or arms called
elephantiasis. Currently, patients in Mali are treated with a single dose of 400 mg of
albendazole plus two doses of 200 mcg/kg of ivermectin each year. This study will use a
regimen of 800 mg of albendazole twice a year plus 200 mcg/kg of ivermectin twice a year for
2 years. The study will see if the new regimen is more effective in lowering the numbers of
Wuchereria bancrofti in the blood and will examine the effects of the two treatments on the
adult worms living in the lymph system.
Healthy people between 14 and 65 years of age who live in the Mali village of N'Tessoni and
are infected with Wuchereria bancrofti may be eligible for this study. Candidates are
screened with a medical history, a brief physical examination and blood tests to check for
infection with Wuchereria bancrofti and to measure white blood cell counts.
Participants undergo the following procedures:
-First visit
Ultrasound examination to look for filarial worms in the body.
Random assignment to receive either standard treatment or the experimental regimen
Urine pregnancy test for women of child-bearing age.
Receive first treatment dose.
-6-month visit
Short history, physical examination and blood test.
Second treatment dose for subjects in experimental treatment group.
Urine pregnancy test for women of childbearing age.
-1-year visit
Short history, physical examination and blood test.
Second or third treatment dose, depending on treatment group.
Repeat ultrasound in subjects whose first ultrasound detected adult worms.
Urine pregnancy test for women of childbearing age.
-18-month visit
Short history, physical examination and blood test.
Fourth treatment dose for subjects in experimental treatment group.
Urine pregnancy test for women of childbearing age.
-24-month visit
Short history, physical examination and blood test.
Repeat ultrasound in subjects whose first ultrasound detected adult worms.
Urine pregnancy test for women of childbearing age.
Albendazole and ivermectin are currently used in combination for annual mass treatment of lymphatic filariasis in Africa. Although the drugs have been donated, the cost of such programs is very high and has proven to be a major impediment to the success of programs in many countries with limited financial resources. Data from albendazole treatment of other filarial infections and one study comparing single to multi-dose DEC/albendazole in lymphatic filariasis suggest that increased dose and/or frequency of albendazole dosing may be more effective in clearing microfilariae. Furthermore, the optimal dose of ivermectin for the treatment of lymphatic filariasis is greater than that being used in the current mass treatment program. In this study, 50 volunteers with microfilaremic Wuchereria bancrofti infection will be randomized to receive standard annual therapy (albendazole 400 mg + ivermectin 150 mcg/kg) or semiannual therapy with an increased albendazole dose (albendazole 800 mg + ivermectin 400 mcg/kg). If adequate numbers of microfilaremic subjects are recruited, an additional 25 volunteers will receive annual therapy with the increased dose combination. Microfilarial levels, as well as measures of adult worm burden (circulating antigen, ultrasound identification of adult worm nests) will be followed every six months for three years to assess the effects of the treatments. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00375583 -
Effect of Albendazole Dose on Clearance of Filarial Worms
|
Phase 2 | |
Completed |
NCT03664063 -
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 2 | |
Recruiting |
NCT04844905 -
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
|
Phase 3 | |
Completed |
NCT01975441 -
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
|
Phase 2 | |
Completed |
NCT01629771 -
Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
|
N/A | |
Completed |
NCT01905423 -
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
|
||
Completed |
NCT02784743 -
Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali
|
Phase 4 | |
Completed |
NCT03036059 -
Twice Yearly Treatment for the Control of LF
|
Phase 4 | |
Completed |
NCT01905436 -
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
|
||
Completed |
NCT02509481 -
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
|
Phase 2/Phase 3 | |
Completed |
NCT03268252 -
Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
|
||
Completed |
NCT02927496 -
A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
|
Phase 3 | |
Completed |
NCT02899936 -
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
|
N/A | |
Completed |
NCT00511004 -
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
|
Phase 2 | |
Active, not recruiting |
NCT04258670 -
Spontaneous Antigenemia in Loiasis
|
||
Completed |
NCT02974049 -
Lymphatic Filariasis (LF) in Ivory Coast
|
N/A | |
Terminated |
NCT01213576 -
Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi
|
N/A | |
Completed |
NCT02929121 -
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
|
Phase 3 | |
Withdrawn |
NCT01903057 -
Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
|
Phase 4 | |
Completed |
NCT02032043 -
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
|